New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer

Author's Avatar
May 24, 2023

Veracyte%2C+Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.